Skip to main content
. 2023 Feb 27;14:1071. doi: 10.1038/s41467-023-35962-x

Fig. 1. Patient disposition.

Fig. 1

CONSORT flow diagram of patient disposition and eligibility in the analysis of mechanisms of acquired resistance in the AURA3 trial. *Plasma provided at baseline and at disease progression or treatment discontinuation. EGFR epidermal growth factor receptor, p.o, orally, qd once daily, TKI tyrosine kinase inhibitor.